

June 7, 2018

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Mothers Code: 4593)
Contact: Ken Ishikawa
Executive Officer in charge of administration
(TEL: 03-5777-8308)

Announcement of Acquisition of MultiStem® License from Athersys

As announced in the press release on March 13, 2018, "[Healios and Athersys Announce Binding Letter of Intent to Expand MultiStem® Collaboration](#)", HEALIOS K.K. ("Healios") entered discussions to expand exclusive license and option rights regarding MultiStem, the proprietary product of Athersys, Inc. ("Athersys"). On May 30, 2018, in the press release "[Announcement of Acquisition of MultiStem® License from Athersys and bank financing](#)", Healios announced that it resolved to acquire the license to develop and commercialize MultiStem as follows and continued negotiations with Athersys.

Exclusive license

In Japan: Development and commercialization for Acute Respiratory Distress Syndrome ("ARDS")

In Japan: Development and commercialization of MultiStem products for Ophthalmology indications

Global: Development and commercialization of organ bud therapies using MultiStem

Today, Healios and Athersys announce that they have agreed to expand their collaboration as follows.

Exclusive license

Global: Development and commercialization of MultiStem products for Ophthalmology indications

Global: Development and commercialization of combination iPS/ES derived cells with MultiStem products in Ophthalmology indications

In Japan: Development and commercialization of combination products of iPS derived organs with MultiStem (for limited organs)

In addition, Healios and Athersys have agreed to extend the negotiation period to expand our collaboration beyond the scope of the above listed areas.

<Overview>

Healios will pay \$10 million for the acquisition of these licenses. Payment will be made in four quarterly instalments, from FY 2018 2nd Quarter. Under the terms of the agreement, Healios will also receive a credit of \$10 million to be used against certain future development milestones.

If matters to be disclosed arise in the future, Healios will promptly make any relevant announcements.